As of 2024-12-15, the EV/EBITDA ratio of Enorama Pharma AB (ERMA.ST) is -4.66. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ERMA.ST's latest enterprise value is 170.45 mil SEK. ERMA.ST's TTM EBITDA according to its financial statements is -36.58 mil SEK. Dividing these 2 quantities gives us the above ERMA.ST EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 4.0x - 11.0x | 7.4x |
| Forward P/E multiples | 5.3x - 9.2x | 7.2x |
| Fair Price | (2.95) - (5.28) | (4.15) |
| Upside | -195.1% - -270.5% | -233.9% |
| Date | EV/EBITDA |
| 2024-12-12 | -4.66 |
| 2024-12-11 | -4.92 |
| 2024-12-10 | -4.99 |
| 2024-12-09 | -4.91 |
| 2024-12-06 | -4.91 |
| 2024-12-05 | -5.25 |
| 2024-12-04 | -5.16 |
| 2024-12-03 | -4.76 |
| 2024-12-02 | -4.96 |
| 2024-11-29 | -5.25 |
| 2024-11-28 | -5.40 |
| 2024-11-27 | -5.50 |
| 2024-11-26 | -5.75 |
| 2024-11-25 | -5.97 |
| 2024-11-22 | -5.77 |
| 2024-11-21 | -5.92 |
| 2024-11-20 | -6.30 |
| 2024-11-19 | -6.53 |
| 2024-11-18 | -6.00 |
| 2024-11-15 | -6.01 |
| 2024-11-14 | -6.06 |
| 2024-11-13 | -6.13 |
| 2024-11-12 | -5.83 |
| 2024-11-11 | -5.80 |
| 2024-11-08 | -5.52 |
| 2024-11-07 | -5.88 |
| 2024-11-06 | -5.88 |
| 2024-11-05 | -6.05 |
| 2024-11-04 | -5.49 |
| 2024-11-01 | -5.62 |
| 2024-10-31 | -5.95 |
| 2024-10-30 | -6.21 |
| 2024-10-29 | -5.78 |
| 2024-10-28 | -5.88 |
| 2024-10-25 | -6.05 |
| 2024-10-24 | -6.08 |
| 2024-10-23 | -5.90 |
| 2024-10-22 | -6.01 |
| 2024-10-21 | -6.15 |
| 2024-10-18 | -6.31 |
| 2024-10-17 | -6.15 |
| 2024-10-16 | -7.16 |
| 2024-10-15 | -6.40 |
| 2024-10-14 | -6.26 |
| 2024-10-11 | -6.48 |
| 2024-10-10 | -6.48 |
| 2024-10-09 | -6.49 |
| 2024-10-08 | -7.12 |
| 2024-10-07 | -7.21 |
| 2024-10-04 | -6.71 |